Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin Alfa with IV Iron for Chemotherapy-Induced Anemia
NCT00401544Phase 2Completed
- Sponsor
- Amgen
- Start
- Dec 2006
- Primary completion
- Dec 2007
- Modality
- Erythropoietins, Colony Stimulating Factors
01
Overview
Phase 2, randomised, open-label trial of darbepoetin alfa in anemia (4 arms), sponsored by Amgen. Primary endpoints: Number of Participants Who Achieved the Target Hemoglobin Level, by Darbepoetin Alfa Dose and Number of Participants Who Achieved the Target Hemoglobin Levels, by IV Iron Usage. Started Dec 2006; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00401544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00401544.